Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC)

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 25-37

  Zhang, Bao Yi ^a   Wang, Yan Ming ^a   Gong, Hai ^a   Zhao, Hui ^a   Lv, Xiao Yan ^a   Yuan, Guang Hui ^a   Han, Shao Rong ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Apoptosis; Cell migration; Chemotherapy; Isorhamnetin; Non small cell lung carcinoma; Tubulin

Indexed keywords

3-METHYLQUERCETIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; QUERCETIN;

ANALOGS AND DERIVATIVES; APOPTOSIS; CELL LINE; CELL SURVIVAL; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; MITOCHONDRIAL MEMBRANE POTENTIAL; NON SMALL CELL LUNG CANCER; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; QUERCETIN;

EID: 84922989550     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Larsen JE, Minna D. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011; 32: 703-740.
2. Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis 2013; 5: S479-90.
3. Tobias J, Hochhauser D. Cancer and its Management. Chapter 12. 6th edition. Wiley-Blackwell; 2010. pp. 200.
4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
5. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006; 8: 30-38.
6. Alberg AJ, Brock MV, Stuart JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol 2005; 23: 3175-3185.
7. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society 2014; [Epub ahead of print].
8. Posther KE, Harpole DH Jr. The surgical management of lung cancer. Cancer Invest 2006; 24: 56-67.
9. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. Lancet Oncol 2011; 12: 1125-1133.
10. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46: 603-10.
11. Li Y, Li H, Hu Y. Clinical study of lymph node metastasis in lung cancer. Chinese J Thorac Cardiovasc Surg 2000; 16: 10-2.
12. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33: 566-74.
13. Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore WF. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979; 44: 1553-62.
14. Drelichman A, Oldford J, Al-Sarraf M. Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma: a phase II study. Am J Clin Oncol 1985; 8: 255-9.
15. Trump DL, Marsh JC, Kvols LK, Citrin D, Davis TE, Hahn RG, Vogl SE. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy: an Eastern Cooperative Group Study. Invest New Drugs 1990; 8: S91-4.
16. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008; 22: 1486-92.
17. Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008; 26: 4001-4011.
18. Murray N, Turrisi AT 3rd. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006; 1: 270-278.
19. Ukena D. Chemotherapy in stage I+II non-small cell lung cancer. Lung Cancer 2001; 33: S25-8.
20. Waller DA. Neoadjuvant chemotherapy in non-small cell lung cancer-the UK experience. Lung Cancer 2001; 34: S31-3.
21. Azim HA, Ganti AK. Treatment options for relapsed small-cell lung cancer. Anticancer Drugs 2007; 18: 255-261.
22. MacCallum C, Gillenwater HH. Second-line treatment of small-cell lung cancer. Curr Oncol Rep 2006; 8: 258-264.
23. Eid SY, El-Readi MZ, Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phyto-medicine 2012; 19: 977-987.
24. Gómez-Contreras PC, Hernández-Flores G, Ortiz-Lazareno PC, Del Toro-Arreola S, Delgado-Rizo V, Lerma-Díaz JM, Barba-Barajas M, Domínguez-Rodríguez JR, Bravo Cuellar A. In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: Increased Bcl-2 and Bax protein expression. Chemotherapy 2006; 52: 308-315.
25. Moffat KA, Johannes WU, Miller GJ. 1, 25-dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999; 5: 695-703.
26. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999; 22: 471-4.
27. Hedley BD, Winquist E, Chambers AF. Therapeutic targets for antimetastatic therapy. Expert Opin TherTargets 2004; 8: 527-536.
28. Chen C, Kong AN. Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 2005; 26: 318-326.
29. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. Expert OpinInvestig Drugs 2004; 13: 1327-1338.
30. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
31. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
32. Maggioni D, Nicolini G, Rigolio R, Biffi L, Pignataro L, Gaini R, Garavello W. Myricetin and Naringenin Inhibit Human Squamous Cell Carcinoma Proliferation and Migration In Vitro. Nutr Cancer 2014; 25: 1-11.
33. Peng C, Zhou K, An S, Yang J. The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer. Tumour Biol 2014; [Epub ahead of print].